

STUDY REPORT SUMMARY

ASTRAZENECA PHARMACEUTICALS

FINISHED PRODUCT: NA

ACTIVE INGREDIENT: NA

Study No: NIS-NZA-XXX-2011/1

Developmental phase: Market Research

Study Completion Date: 15/10/2010

Date of Report: 15/12/2010

OBJECTIVES: To evaluate the patient management for Schizophrenia, Bipolar disorders and MDD.

METHODS: ‘Real life’ retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.

RESULTS:

Majority of the current Seroquel patients (54%) were previously on another branded drug

Therefore, for Seroquel, 81% of change in treatment is based on change of dosage/formulation of Seroquel

In addition, if patient was previously on Seroquel, there is very little to no chance of them being prescribed Risperdal